TPC - Biochem Pharma (en francais)

BIOCHEM PHARMA INC.
To combat the large number of cases of respiratory infections worldwide, Laval, Quebec-based BioChemPharma Inc. is developing an innovative vaccine program that promises safer, cheaper and more effective protection against pneumonia, meningitis, and streptococcus — diseases considered health priorities by the World Health Organization and Health Canada. As the project evolves, BioChem Pharma is committed to expanding its current research capability and to establishing a research centre or centres in Canada to further develop this and other state-of-the-art vaccine technologies and to produce the vaccines in Canada in a new facility.

TPC approved repayable R&D investment: $80 million

Minister - Alan Rock

Lobbyists:
BELLINI, FRANCESCO 2000/02/21 2001/02/28
BELLINI, FRANCESCO 2001/02/28 2002/03/01
CHASE, RANDAL 2001/02/26 2002/03/01
CHOUINARD, MICHEL 2000/02/21 2001/02/28
CHOUINARD, MICHEL 2001/02/28 2002/03/01
DUGRÉ, ROBERT 2001/02/26 2002/03/01
LAPOINTE, JACQUES 2000/02/21 2001/02/28
LAPOINTE, JACQUES 2001/02/28 2002/03/01
LORD, GUY 1999/08/12 2000/02/21
LORD, GUY 2000/02/21 2001/02/08
LORD, GUY 2001/02/20 2002/03/01
SHELDON, ANDY 2001/02/26 2002/03/01
DUFOUR, GHISLAIN 1998/08/11 N/A

Note: some of these registrations have the "I: Contingency Fees:" category, others do not.

Biochem Pharma Political Donations 1996 - 2004
1996 - $3,845.07 Liberal Party
1997 - $3,723.00 Progressive Conservative Party
1997 - $3,671.34 Liberal Party
1998 - $3,632.15 Liberal Party
1999 - 0
2000 - $64,742.30 Liberal Party
2000 - $5,000.00 Canadian Alliance/Reform Party
2000 - $673.52 Bloc Québécois
2001 - $4,346.30 Liberal Party
2001 - $56,536.25 Liberal Party (Shire Biochem)
2002 - $4,305.50 Liberal Party (Shire Biochem)
2003 - $12,309.68 Liberal Party (Shire Biochem)

Related Items: Jacques Lapointe - Bioniche

Guy Lord - Millenium Scholarship Fund

Francesco Bellini - Neurochem Inc
NEUROCHEM INC.
Developing an effective treatment for the estimated 14.5 million North Americans currently afflicted with Alzheimer’s disease is the focus of clinical trials being conducted by Neurochem Inc. of Saint-Laurent, Quebec. Neurochem’s therapeutic drug aims to prevent and arrest the brain cell death that leads to Alzheimer’s disease. If successful, this drug could considerably reduce the number of people developing Alzheimer’s disease and also reduce the nearly $4 billion Canada spends each year on health care costs related to Alzheimer’s disease and other dementias.

TPC approved repayable R&D investment: $7.9 million

Note: I'll cover the rest of Neurochem in detail later.

(Cross posted from Technoscam)